KORU MEDICAL SYSTEMS INC (KRMD)
US7599101026 - Common Stock
Taking everything into account, KRMD scores 3 out of 10 in our fundamental rating. KRMD was compared to 192 industry peers in the Health Care Equipment & Supplies industry. The financial health of KRMD is average, but there are quite some concerns on its profitability. While showing a medium growth rate, KRMD is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year KRMD has reported negative net income.
In the past year KRMD has reported a negative cash flow from operations.
KRMD had negative earnings in 4 of the past 5 years.
KRMD had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
KRMD has a worse Return On Assets (-48.29%) than 66.15% of its industry peers.
KRMD's Return On Equity of -67.53% is in line compared to the rest of the industry. KRMD outperforms 41.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.29% | ||
| ROE | -67.53% | ||
| ROIC | N/A |
ROA(3y)-26.59%
ROA(5y)-15.76%
ROE(3y)-35.88%
ROE(5y)-21.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KRMD has a Gross Margin (58.60%) which is in line with its industry peers.
KRMD's Gross Margin has been stable in the last couple of years.
KRMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.76%
GM growth 5Y-1.22%
2. Health
2.1 Basic Checks
KRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KRMD has more shares outstanding
KRMD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for KRMD is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.67 indicates that KRMD is not in any danger for bankruptcy at the moment.
KRMD has a better Altman-Z score (6.67) than 83.33% of its industry peers.
KRMD has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
KRMD's Debt to Equity ratio of 0.03 is fine compared to the rest of the industry. KRMD outperforms 63.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.67 |
ROIC/WACCN/A
WACC10.02%
2.3 Liquidity
KRMD has a Current Ratio of 4.55. This indicates that KRMD is financially healthy and has no problem in meeting its short term obligations.
KRMD's Current ratio of 4.55 is fine compared to the rest of the industry. KRMD outperforms 64.58% of its industry peers.
KRMD has a Quick Ratio of 3.77. This indicates that KRMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.77, KRMD is in the better half of the industry, outperforming 66.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.55 | ||
| Quick Ratio | 3.77 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.00% over the past year.
KRMD shows a small growth in Revenue. In the last year, the Revenue has grown by 2.26%.
Measured over the past years, KRMD shows a quite strong growth in Revenue. The Revenue has been growing by 10.45% on average per year.
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q50%
Revenue 1Y (TTM)2.26%
Revenue growth 3Y5.65%
Revenue growth 5Y10.45%
Revenue growth Q2Q-2.1%
3.2 Future
KRMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.07% yearly.
Based on estimates for the next years, KRMD will show a quite strong growth in Revenue. The Revenue will grow by 12.04% on average per year.
EPS Next Y28.6%
EPS Next 2Y26.58%
EPS Next 3Y23.07%
EPS Next 5YN/A
Revenue Next Year-3.09%
Revenue Next 2Y8.7%
Revenue Next 3Y12.04%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KRMD. In the last year negative earnings were reported.
Also next year KRMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as KRMD's earnings are expected to grow with 23.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.58%
EPS Next 3Y23.07%
5. Dividend
5.1 Amount
KRMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KORU MEDICAL SYSTEMS INC
NASDAQ:KRMD (5/1/2024, 9:30:20 AM)
2.2
+0.03 (+1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap100.56M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.29% | ||
| ROE | -67.53% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.6% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.55 | ||
| Quick Ratio | 3.77 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y28.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)2.26%
Revenue growth 3Y5.65%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y